Interleukin I receptor associated kinase 1 (IRAK1)
is a downstream signal molecule of activated MyD88 recruitment, which can
activate Fas associated death domain protein (FADD) to induce apoptosis. IRAK1
can also activate tumor necrosis factor-related factor 6 (TRAF6) and induce the
expression of a series of downstream specific genes. IRAK1 is an essential
factor in the induction of mitochondrial division and necroptosis. In the
current study, RNAi technique was used to silence IRAK1, and the apoptosis and necroptosis
rate of SK-Hep1 cells were detected by flow cytometry. The apoptosis and the
necroptosis pathway of hepatoma SK-Hep1 cells were blocked separately, and the
expressions of FADD, RIP1 and TRAF6 genes were silenced separately. The results showed when the expression of
IRAK1 was down-regulated, the apoptosis and necroptosis rate of SK-Hep1
cells were significantly increased. With silenced FADD, RIP1 and TRAF6,
respectively, the expression of IRAK1 protein had no significant change.
However, the expression of IRAK1 mRNA decreased significantly (p < 0.01)
after the silencing of RIP1 and TRAF6 genes, while the IRAK1 mRNA did not
change significantly after the silencing of FADD genes; when z-VAD-FMK was
interfered, the expression of IRAK1 mRNA decreased significantly after the
silencing of TRAF6 genes, while the IRAK1 mRNA did not change significantly
after the silencing of FADD and RIP1genes. The study shows that RAK1 gene
inhibits apoptosis and necroptosis in SK-Hep1 cells. TRAF6 gene affected the
role of IRAK1 in apoptosis and necroptosis, RIP1 gene affected the role of
IRAK1 in apoptosis, while FADD gene did not affect the role of IRAK1 in
apoptosis and necroptosis.
References
[1]
Chen, C.J., Yu, M.W. and Liaw, Y.F. (1997) Epidemiological Characteristics and Risk Factors of Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 12, S294-S308. https://doi.org/10.1111/j.1440-1746.1997.tb00513.x
[2]
Oda, T., Tsuda, H., Scarpa, A., Sakamoto, M. and Hirohashi, S. (1992) p53 Gene Mutation Spectrum in Hepatocellular Carcinoma. Cancer Research, 52, 6358-6364.
[3]
Farshid, M., Hsia, C.C. and Tabor, E. (1994) Alterations of the RB Tumour Suppressor Gene in Hepatocellular Carcinoma and Hepatoblastoma Cell Lines in Association with Abnormal p53 Expression. Journal of Viral Hepatitis, 1, 45-53.
https://doi.org/10.1111/j.1365-2893.1994.tb00061.x
[4]
Wan, X.W., Jiang, M., Cao, H.F., et al. (2003) The Alteration of PTEN Tumor Suppressor Expression and Its Association with the Histopathological Features of Human Primary Hepatocellular Carcinoma. Journal of Cancer Research and Clinical Oncology, 129, 100-106.
[5]
Tiniakos, D., Spandidos, D.A., Kakkanas, A., Pintzas, A., Pollice, L. and Tiniakos, G. (1989) Expression of Ras and Myc Oncogenes in Human Hepatocellular Carcinoma and Non-Neoplastic Liver Tissues. Anticancer Research, 9, 715-721.
[6]
El-Serag, H.B. and Rudolph, K.L. (2007) Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology, 132, 2557-2576.
https://doi.org/10.1053/j.gastro.2007.04.061
[7]
Akira, S. and Takeda, K. (2004) Toll-Like Receptor Signaling. Nature Reviews Immunology, 4, 499-511. https://doi.org/10.1038/nri1391
[8]
Baker, B., Maitra, U., Geng, S. and Li, L. (2014) Molecular and Cellular Mechanisms Responsible for Cellular Stress and Low-Grade Inflammation Induced by a Super-Low Dose of Endotoxin. Journal of Biological Chemistry, 289, 16262-16269.
https://doi.org/10.1074/jbc.M114.569210
Dillon, C.P., Weinlich, R., Rodriguez, D.A., et al. (2014) RIPK1 Blocks Early Postnatal Lethality Mediated by Caspase-8 and RIPK3. Cell, 157, 1189-1202.
https://doi.org/10.1016/j.cell.2014.04.018
[11]
Kim, J.M., Cho, H.H., Lee, S.Y., et al. (2012) Role of IRAK1 on TNF-Induced Proliferation and NF-kB Activation in Human Bone Marrow Mesenchymal Stem Cells. Cellular Physiology and Biochemistry, 30, 49-60. https://doi.org/10.1159/000339045
[12]
Li, X., Liu, C., Ip, B.C., et al. (2015) Tumor Progression Locus 2 Ablation Suppressed Hepatocellular Carcinoma Development by Inhibiting Hepatic Inflammation and Steatosis in Mice. Journal of Experimental and Clinical Cancer Research, 34, 138. https://doi.org/10.1186/s13046-015-0254-2
[13]
Li, L., Xu, L., Yan, J., et al. (2015) CXCR2-CXCL1 Axis Is Correlated with Neutrophil Infiltration and Predicts a Poor Prognosis in Hepatocellular Carcinoma. Journal of Experimental and Clinical Cancer Research, 34, 129.
https://doi.org/10.1186/s13046-015-0247-1
[14]
Rhyasen, G.W., Bolanos, L., Fang, J., et al. (2013) Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. Cancer Cell, 24, 90-104.
https://doi.org/10.1016/j.ccr.2013.05.006
[15]
Zhang, X., Dang, Y., Li, P., Rong, M. and Chen, G. (2014) Expression of IRAK1 in Lung Cancer Tissues and Its Clinicopathological Significance: A Microarray Study. International Journal of Clinical and Experimental Pathology, 7, 8096-8104.
[16]
Wee, Z.N., Yatim, S.M., Kohlbauer, V.K., et al. (2015) IRAK1 Is a Therapeutic Target That Drives Breast Cancer Metastasis and Resistance to Paclitaxel. Nature Communications, 6, Article No. 8746.
[17]
Huang, Y.S., Misior, A. and Li, L.W. (2005) Novel Role and Regulation of the Interleukin-1 Receptor Associated Kinase (IRAK) Family Proteins. Cellular & Molecular Immunology, 2, 36-39.
[18]
Rhyasen, G.W. and Starczynowski, D.T. (2015) IRAK Signalling in Cancer. British Journal of Cancer, 112, 232-237. https://doi.org/10.1038/bjc.2014.513
[19]
Feitelson, M.A., Arzumanyan, A., Kulathinal, R.J., et al. (2015) Sustained Proliferation in Cancer: Mechanisms and Novel Therapeutic Targets. Seminars in Cancer Biology, 35, S25-S54.
[20]
Deng, L., Yang, H., Tang, J., et al. (2015) Inhibition of MTA1 by ERalpha Contributes to Protection Hepatocellular Carcinoma from Tumor Proliferation and Metastasis. Journal of Experimental & Clinical Cancer Research, 34, 128.
https://doi.org/10.1186/s13046-015-0248-0
[21]
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T. and Kroemer, G. (2010) Molecular Mechanisms of Necroptosis: An Ordered Cellular Explosion. Nature Reviews Molecular Cell Biology, 11, 700-714. https://doi.org/10.1038/nrm2970
[22]
Holler, N., Zaru, R., Micheau, O., et al. (2000) Fas Triggers an Alternative, Caspase-8 Independent Cell Death Pathway Using the Kinase RIP as Effector Molecule. Nature Immunology, 1, 489-495. https://doi.org/10.1038/82732
[23]
Degterev, A., Huang, Z., Boyce, M., et al. (2005) Chemical Inhibitor of Nonapoptotic Cell Death with Therapeutic Potential for Ischemic Brain Injury. Nature Chemical Biology, 1, 112-119. https://doi.org/10.1038/nchembio711
[24]
Degterev, A., Hitomi, J., Germscheid, M., et al. (2008) Identification of RIP1 Kinase as a Specific Cellular Target of Necrostatins. Nature Chemical Biology, 4, 313-321.
https://doi.org/10.1038/nchembio.83
[25]
Bonnet, M.C., Preukschat, D., Welz, P.S., et al. (2011) The Adaptor Protein FADD Protects Epidermal Keratinocytes from Necroptosis in Vivo and Prevents Skin Inflammation. Immunity, 35, 572-582. https://doi.org/10.1016/j.immuni.2011.08.014
[26]
Lu, J.V., Weist, B.M., van Raam, B.J., et al. (2011) Complementary Roles of FAS-Associated Death Domain (FADD) and Receptor Interacting Protein Kinase-3 (RIPK3) in T-Cell Homeostasis and Antiviral Immunity. Proceedings of the National Academy of Sciences, 108, 15312-15317.
https://doi.org/10.1073/pnas.1102779108
[27]
Lee, E.W., Seo, J.H., Jeong, M.H., Lee, S.S. and Song, J.W. (2012) The Roles of FADD in Extrinsic Apoptosis and Necroptosis. BMB Reports, 45, 496-508.
https://doi.org/10.5483/BMBRep.2012.45.9.186
[28]
Cullen, S.P., Henry, C.M., Kearney, C.J., et al. (2013) Fas/CD95-Induced Chemokines Can Serve as “Find-Me” Signals for Apoptotic Cells. Molecular Cell, 49, 1034-1038. https://doi.org/10.1016/j.molcel.2013.01.025
[29]
Tenev, T., Bianchi, K., Darding, M., et al. (2011) The Ripop-Tosome, a Signaling Platform That Assembles in Response to Genotoxic Stress and Loss of IAPs. Molecular Cell, 43, 432-448. https://doi.org/10.1016/j.molcel.2011.06.006
